ArticleMetabolites2025
Altered Carnitine Metabolism in Ischemic and Non-Ischemic Cardiomyopathy: A Comparative Metabolomics Study Using LC-MS/MS.
Article in Metabolites, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiomyopathy is a major cause of heart failure. Ischemic cardiomyopathy (IC) and non-ischemic cardiomyopathy (NIC) have distinct pathophysiological mechanisms. Carnitine plays a critical role in transporting long-chain fatty acids into mitochondria for β-oxidation. Disruptions in carnitine and acylcarnitine homeostasis have been implicated in cardiomyopathy; however, comparative profiling between IC and NIC remains limited.
methodsSerum samples were obtained from 40 IC patients, 40 NIC patients, and 40 age- and sex-matched controls. Free carnitine and 27 acylcarnitine species were quantified using LC-MS/MS. Multivariate analyses (PCA, PLS-DA), univariate statistics (ANOVA with Tukey's HSD), and ROC curve analyses were performed to identify discriminatory metabolites and assess their diagnostic performance.
resultsCompared with controls, IC patients exhibited reduced levels of short- and medium-chain acylcarnitines (C2, C4DC, C6, C8, C10, and C14), whereas NIC patients showed elevations in medium- and long-chain species (C6DC and C16). Heatmaps demonstrated clear group clustering. PCA and PLS-DA revealed partial separation, with C2, C6DC, and C16 emerging as the most influential metabolites (highest VIP scores). ROC analysis indicated modest diagnostic performance, with AUC values ranging from 0.623 to 0.635.
conclusionsIC and NIC are characterized by distinct alterations in serum carnitine profiles, reflecting differential metabolic remodeling. These findings may clarify disease mechanisms and highlight potential metabolic biomarkers or therapeutic targets. Acylcarnitine profiling could support differential diagnosis and personalized management in cardiomyopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.